GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » Short-Term Debt

Maat Pharma (XPAR:MAAT) Short-Term Debt : €6.19 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma Short-Term Debt?

Maat Pharma's Short-Term Debt for the quarter that ended in Jun. 2024 was €6.19 Mil.

Maat Pharma's quarterly Short-Term Debt declined from Jun. 2023 (€5.85 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Jun. 2024 (€6.19 Mil).

Maat Pharma's annual Short-Term Debt increased from Dec. 2021 (€1.08 Mil) to Dec. 2022 (€2.79 Mil) but then declined from Dec. 2022 (€2.79 Mil) to Dec. 2023 (€0.00 Mil).


Maat Pharma Short-Term Debt Historical Data

The historical data trend for Maat Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma Short-Term Debt Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial 0.55 0.78 1.08 2.79 -

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.24 2.79 5.85 - 6.19

Maat Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Maat Pharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Maat Pharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Maat Pharma Business Description

Traded in Other Exchanges
Address
70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma Headlines

No Headlines